At 6.3% CAGR, Europe Infusion Devices Market is Projected to be Worth US$ 6,590.36 Million by 2031, says The Insights Partners

According to The Insights Partners research, the Europe infusion devices market was valued at US$ 4,047.05 million in 2023 and is expected to reach US$ 6,590.36 million by 2031, registering a CAGR of 6.3% from 2023 to 2031. Strategic initiatives by market players and growing geriatric population are among the critical factors attributed to driving the Europe infusion devices market growth.

Various market players focus on strategic developments such as product launches, mergers, acquisitions, and collaborations to develop advanced products that ease the treatment of chronic disorders such as diabetes, cancer, and chronic pain. The following are a few recent developments in the Europe infusion devices market. In February 2023, Mindray launched its BeneFusion i Series and u Series infusion systems, featuring high precision, adaptive customization and extraordinary simplicity for guaranteed levels of medication safety in a variety of clinical settings. In November 2022, Medtronic plc announced the launch of Medtronic Extended infusion set in the US. It is the first and only infusion set labeled for up to seven-day wear. An infusion set is a tubing that delivers insulin from an insulin pump to the body and usually needs to be changed every two to three days. In March 2022, Fresenius Kabi received 510(k) regulatory clearance from the FDA for its wireless Agilia Connect Infusion System. The system includes Agilia Volumetric Pump and Agilia Syringe Pump with Vigilant Software Suite-Vigilant Master Med technology. Both pumps are the first to be cleared following TIR101 standards, which were developed by the Association for the Advancement of Medical Instrumentation (AAMI) in 2021. In April 2021, in Europe, Medtronic launched the Medtronic Extended infusion set. It is the first and only infusion set that can be worn for up to 7 days. In January 2021, Eitan Medical, a global leader in advanced infusion therapy, launched a UK operation to improve its support of Sapphire infusion pump customers, which include NHS Trusts, private hospitals, and home care providers. An upsurge in the number of product approvals, launches, and strategic collaborations is likely to create lucrative opportunities for the infusion devices market in the future.

On the contrary, frequent product recalls of infusion devices hamper the growth of Europe infusion devices market .

By product type, the Europe infusion devices market is bifurcated into infusion pumps and infusion sets. The infusion pumps held 75.1% share of Europe infusion devices market share in 2023, amassing US$ 3,041.17 million. It is projected to garner US$ 5,018.92 million by 2031 to register 6.5% CAGR during 2023-2031.

In terms of infusion pumps, the market is segmented into volumetric pumps, syringe pumps, insulin pumps, patient control analgesia (PCA) pumps, enteral pumps, implantable pumps, and elastomeric pumps. The volumetric pumps segment held 29.0% share of Europe infusion devices market share in 2023, amassing US$ 882.20 million. It is projected to garner US$ 1,410.85 million by 2031 to register 6.0% CAGR during 2023-2031.

By infusion sets, the Europe infusion devices market is segmented into vented infusion sets and non-vented infusion sets. The vented infusion sets held 61.2% share of Europe infusion devices market share in 2023, amassing US$ 615.14 million. It is projected to garner US$ 982.96 million by 2031 to register 6.0% CAGR during 2023-2031.

By application, the Europe infusion devices market is segmented into diabetes, oncology, pain management, hematology, pediatrics, gastroenterology, and others. The diabetes held 37.5% share of Europe infusion devices market share in 2023, amassing US$ 1,518.37 million. It is projected to garner US$ 2,572.42 million by 2031 to register 6.8% CAGR during 2023-2031.

By end user, the Europe infusion devices market is segmented into hospitals and specialty clinics, homecare settings, ambulatory surgical centers, and others. The hospitals and specialty clinics held 53.8% share of Europe infusion devices market share in 2023, amassing US$ 2,176.75 million. It is projected to garner US$ 3,524.40 million by 2031 to register 6.2% CAGR during 2023-2031.

Based on country, the Europe infusion devices market is categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 26.5% share of Europe infusion devices market in 2023. It was assessed at US$ 1,072.53 million in 2023 and is likely to hit US$ 1,770.25 million by 2031, registering a CAGR of 6.5% during 2023-2031.

Key players operating in the infusion devices market are B Braun SE, Baxter International Inc, Becton Dickinson and Co, BPL Medical Technologies Pvt Ltd, CODAN US Corp, Eitan Medical Ltd, Elimedical Inc, Fresenius Kabi AG, ICU Medical Inc, KD Scientific Inc, Medtronic Plc, Moog Inc, Nipro Corp, Polymedicure, Tandem Diabetes Care Inc, Terumo Corp, and Zimed Healthcare Ltd, among others.

In May-2024: Moog Inc. received US FDA 510(k) clearance for CURLIN 8000 Ambulatory Infusion System. This premium infusion platform was developed specifically for use in home infusion settings. The CURLIN 8000 combines a reliable and robust design with a simple, intuitive user interface designed for easy navigation by both clinical and non-clinical users. The CURLIN 8000 also integrates seamlessly with CURLIN RxManager, a completely new medication safety software developed to complement existing home infusion workflows.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com